41.50
price down icon2.21%   -0.94
after-market After Hours: 41.50
loading
Tarsus Pharmaceuticals Inc stock is traded at $41.50, with a volume of 442.11K. It is down -2.21% in the last 24 hours and up +3.23% over the past month. Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
See More
Previous Close:
$42.44
Open:
$42.54
24h Volume:
442.11K
Relative Volume:
0.70
Market Cap:
$1.74B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-8.944
EPS:
-4.64
Net Cash Flow:
$-123.00M
1W Performance:
-4.05%
1M Performance:
+3.23%
6M Performance:
-14.92%
1Y Performance:
+46.95%
1-Day Range:
Value
$40.75
$42.54
1-Week Range:
Value
$40.75
$43.55
52-Week Range:
Value
$20.08
$57.28

Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile

Name
Name
Tarsus Pharmaceuticals Inc
Name
Phone
(949) 409-9820
Name
Address
15440 LAGUNA CANYON ROAD, IRVINE
Name
Employee
323
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
TARS's Discussions on Twitter

Compare TARS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TARS
Tarsus Pharmaceuticals Inc
41.50 1.78B 17.39M -135.89M -123.00M -4.64
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-02-25 Resumed Oppenheimer Outperform
May-27-25 Resumed H.C. Wainwright Buy
Nov-20-23 Initiated Goldman Neutral
Jul-18-23 Initiated William Blair Outperform
May-18-23 Initiated Guggenheim Buy
Aug-01-22 Initiated Barclays Overweight
Dec-21-21 Initiated H.C. Wainwright Buy
Nov-23-21 Initiated Oppenheimer Outperform
Nov-10-20 Initiated BofA Securities Buy
Nov-10-20 Initiated Jefferies Buy
Nov-10-20 Initiated Ladenburg Thalmann Buy
Nov-10-20 Initiated Raymond James Strong Buy
View All

Tarsus Pharmaceuticals Inc Stock (TARS) Latest News

pulisher
Jul 25, 2025

Bank of New York Mellon Corp Sells 915 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World

Jul 25, 2025
pulisher
Jul 25, 2025

Should I buy Tarsus Pharmaceuticals Inc. stock before earningsMarket-crushing profits - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

Is Tarsus Pharmaceuticals Inc. a good long term investmentOutstanding growth strategies - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Path To Profitability - Yahoo Finance

Jul 24, 2025
pulisher
Jul 23, 2025

Tarsus Pharmaceuticals Inc. Stock Analysis and ForecastHigh-return market picks - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Tarsus Pharmaceuticals Inc. stockHigh-yield portfolio picks - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Arizona State Retirement System Purchases 470 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Tarsus Pharmaceuticals Inc. stock priceBreakthrough wealth creation - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

What makes Tarsus Pharmaceuticals Inc. stock price move sharplyFree Stock Movement Tracking - Newser

Jul 22, 2025
pulisher
Jul 19, 2025

Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Tarsus Pharmaceuticals (TARS) and Abbott Laboratories (ABT) - The Globe and Mail

Jul 19, 2025
pulisher
Jul 18, 2025

Tarsus Pharmaceuticals Shares Soar 4.47% on Strong Sales, Earnings - AInvest

Jul 18, 2025
pulisher
Jul 17, 2025

Tarsus Pharmaceuticals: A Compelling Case for Investment in the Era of Anterior Segment Innovation - AInvest

Jul 17, 2025
pulisher
Jul 17, 2025

Tarsus Pharmaceuticals: Making Big Strides (NASDAQ:TARS) - Seeking Alpha

Jul 17, 2025
pulisher
Jul 17, 2025

William Blair Has Bearish Estimate for TARS Q2 Earnings - Defense World

Jul 17, 2025
pulisher
Jul 16, 2025

What is William Blair’s Forecast for TARS FY2026 Earnings? - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

How Tarsus Pharmaceuticals Inc. stock performs during market volatilityFree Investment Risk Control - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Tarsus Pharmaceuticals Inc. stock attracts strong analyst attentionHigh Return Potential - Newser

Jul 15, 2025
pulisher
Jul 13, 2025

Bank of America Securities Reaffirms Buy Rating for Tarsus Pharmaceuticals at $68.00 - AInvest

Jul 13, 2025
pulisher
Jul 12, 2025

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Amalgamated Bank - Defense World

Jul 12, 2025
pulisher
Jul 12, 2025

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of “Buy” by Analysts - Defense World

Jul 12, 2025
pulisher
Jul 08, 2025

(TARS) Investment Analysis - news.stocktradersdaily.com

Jul 08, 2025
pulisher
Jul 02, 2025

Market Sentiment Around Loss-Making Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - simplywall.st

Jul 02, 2025
pulisher
Jul 01, 2025

Janney Montgomery Scott LLC Sells 2,795 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World

Jul 01, 2025
pulisher
Jun 30, 2025

Tarsus Pharmaceuticals, Inc.(NasdaqGS:TARS) dropped from Russell Microcap Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 19, 2025

Tarsus Pharmaceuticals (NASDAQ:TARS) versus Protalix BioTherapeutics (NYSE:PLX) Financial Comparison - Defense World

Jun 19, 2025
pulisher
Jun 18, 2025

Tarsus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 18, 2025
pulisher
Jun 17, 2025

Tarsus Pharmaceuticals Becomes Oversold (TARS) - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

When (TARS) Moves Investors should Listen - news.stocktradersdaily.com

Jun 17, 2025
pulisher
Jun 17, 2025

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of “Buy” by Brokerages - Defense World

Jun 17, 2025
pulisher
Jun 16, 2025

Rhumbline Advisers Increases Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World

Jun 16, 2025
pulisher
Jun 12, 2025

Tarsus Pharmaceuticals’ SWOT analysis: XDEMVY’s success propels stock growth - Investing.com Australia

Jun 12, 2025
pulisher
Jun 12, 2025

Tarsus Pharmaceuticals’ SWOT analysis: XDEMVY’s success propels stock growth By Investing.com - Investing.com India

Jun 12, 2025
pulisher
Jun 12, 2025

Insider Sell: Aziz Mottiwala Sells 17,500 Shares of Tarsus Pharm - GuruFocus

Jun 12, 2025
pulisher
Jun 11, 2025

Tarsus Pharmaceuticals CCO sells $765,800 in stock - Investing.com Australia

Jun 11, 2025
pulisher
Jun 11, 2025

Tarsus Pharmaceuticals CCO sells $765,800 in stock By Investing.com - Investing.com Canada

Jun 11, 2025

Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):